Literature DB >> 16455654

c-Met expression is regulated by Mitf in the melanocyte lineage.

Gaël G McGill1, Rizwan Haq, Emi K Nishimura, David E Fisher.   

Abstract

Hepatocyte growth factor (HGF)/c-Met signaling is thought to be a key pathway in both melanocyte development and melanoma metastasis. Here, HGF stimulation of melanocytes was seen to up-regulate c-Met expression. In an effort to decipher the mechanism by which HGF up-regulates its receptor, we found that c-Met is a direct transcriptional target of Mitf. This was confirmed with chromatin immunoprecipitation experiments of the human c-Met promoter, as well as by the ability of adenovirally expressed Mitf to modulate endogenous c-Met protein levels in melanocytes. Disruption of Mitf blocked HGF-dependent increases in endogenous c-Met message and protein levels, indicating that HGF regulates its own receptor levels via Mitf. Finally, dominant-negative inhibition of Mitf resulted in profound resistance of melanocytes and melanoma cells to HGF-dependent matrix invasion, suggesting a physiologic role for this pathway in melanocytic development and melanoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455654     DOI: 10.1074/jbc.M513094200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Therapeutic targets in melanoma: map kinase pathway.

Authors:  Frank G Haluska; Nageatte Ibrahim
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 3.  The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.

Authors:  Akinori Kawakami; David E Fisher
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

Review 4.  Advances in sarcoma genomics and new therapeutic targets.

Authors:  Barry S Taylor; Jordi Barretina; Robert G Maki; Cristina R Antonescu; Samuel Singer; Marc Ladanyi
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

Review 5.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

6.  Regulation of MITF stability by the USP13 deubiquitinase.

Authors:  Xiansi Zhao; Brian Fiske; Akinori Kawakami; Juying Li; David E Fisher
Journal:  Nat Commun       Date:  2011-08-02       Impact factor: 14.919

7.  The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Authors:  Adam I Riker; Steven A Enkemann; Oystein Fodstad; Suhu Liu; Suping Ren; Christopher Morris; Yaguang Xi; Paul Howell; Brandon Metge; Rajeev S Samant; Lalita A Shevde; Wenbin Li; Steven Eschrich; Adil Daud; Jingfang Ju; Jaime Matta
Journal:  BMC Med Genomics       Date:  2008-04-28       Impact factor: 3.063

8.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

9.  Gpnmb is a melanoblast-expressed, MITF-dependent gene.

Authors:  Stacie K Loftus; Anthony Antonellis; Ivana Matera; Gabriel Renaud; Laura L Baxter; Duncan Reid; Tyra G Wolfsberg; Yidong Chen; Chenwei Wang; Megana K Prasad; Seneca L Bessling; Andrew S McCallion; Eric D Green; Dorothy C Bennett; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2008-11-01       Impact factor: 4.693

Review 10.  Small molecules and targeted therapies in distant metastatic disease.

Authors:  P Hersey; L Bastholt; V Chiarion-Sileni; G Cinat; R Dummer; A M M Eggermont; E Espinosa; A Hauschild; I Quirt; C Robert; D Schadendorf
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.